tirofiban has been researched along with Coronary Restenosis in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Wang, B; Wang, W; Wei, S | 1 |
| Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S | 1 |
| Bolsin, S; Conroy, M; Osborne, C | 1 |
| Boes, L; Bonz, AW; Ertl, G; Lengenfelder, B; Stoerk, S; Strotmann, J; Voelker, W | 1 |
| Controtto, F; Cristofori, R; D'Amico, M; Grasso, C; Marra, S; Pennone, M; Scacciatella, P | 1 |
| Harrington, RA; Nguyen, CM | 1 |
| Day, JR; Haskard, DO; Landis, RC; Malik, IS; Nadra, I; Poullis, M; Taylor, KM; Weerasinghe, A | 1 |
| Ansani, L; Barbieri, D; Bettini, A; Campo, G; Cicchitelli, G; Ferrari, F; Ferrari, R; Guardigli, G; Malagutti, P; Parrinello, G; Percoco, G; Soukhomovskaia, O; Valgimigli, M | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Azar, RR; Badaoui, G; Germanos, M; Kassab, R; Klaymé, S; Naman, R; Salamé, E; Sarkis, A | 1 |
| Baum, H; Braun, S; Dibra, A; Dirschinger, J; Hadamitzky, M; Kastrati, A; Mehilli, J; Schömig, A; Schühlen, H | 1 |
| Chang, M; Dangas, G; Ellis, SG; Kao, J; Laufer, N; Mehran, R; Russell, ME; Stone, GW; Tannenbaum, MA; Teirstein, PS; Watkins, M | 1 |
| Jain, D; Khattab, AA; Kurowski, V; Richardt, G; Richter, C; Toelg, R; Wiegand, UK | 1 |
| Aguiar, C; Almeida, M; de Araujo Goncalves, P; Ferreira, J; Pereira Machado, F; Raposo, L; Seabra-Gomes, R; Teles, R | 1 |
| Arcozzi, C; Barbieri, D; Campo, G; Carletti, R; Ferrari, F; Ferrari, R; Malagutti, P; Parrinello, G; Percoco, G; Valgimigli, M | 1 |
| Sajid, M; Stouffer, GA | 1 |
3 review(s) available for tirofiban and Coronary Restenosis
| Article | Year |
|---|---|
Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.
Topics: Abciximab; Angioplasty; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Restenosis; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombosis; Tirofiban; Tyrosine | 2003 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
The role of alpha(v)beta3 integrins in vascular healing.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Adhesion; Chemotaxis, Leukocyte; Clinical Trials as Topic; Coronary Restenosis; Coronary Stenosis; Drug Evaluation, Preclinical; Endothelium, Vascular; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Models, Animal; Papio; Peptides; Platelet Adhesiveness; Rabbits; Rats; Receptors, Vitronectin; Signal Transduction; Swine; Tirofiban; Tyrosine; Vasculitis; Wound Healing | 2002 |
7 trial(s) available for tirofiban and Coronary Restenosis
| Article | Year |
|---|---|
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug-Eluting Stents; Emergencies; Female; Hemostasis, Surgical; Humans; Male; Middle Aged; Perioperative Care; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Substance Withdrawal Syndrome; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Troponin; Tyrosine | 2011 |
High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Protocols; Coronary Restenosis; Drug Implants; Drug Therapy, Combination; Electrocardiography; Female; Forecasting; Humans; Immunoglobulin Fab Fragments; Injections; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; C-Reactive Protein; CD40 Ligand; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Creatine Kinase; Creatine Kinase, MB Form; Double-Blind Method; Drug Interactions; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Paclitaxel; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Restenosis; Female; Fibrinolytic Agents; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Pilot Projects; Saphenous Vein; Stents; Tirofiban; Treatment Outcome; Troponin T; Tyrosine; Ultrasonography, Doppler; Ultrasonography, Interventional | 2005 |
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Restenosis; Disease-Free Survival; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Prosthesis Design; Risk; Sirolimus; Stents; Tirofiban; Tyrosine | 2007 |
6 other study(ies) available for tirofiban and Coronary Restenosis
| Article | Year |
|---|---|
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Occlusion; Coronary Restenosis; Cytochrome P-450 CYP2C19; Dual Anti-Platelet Therapy; Female; Fibrinolytic Agents; Humans; Integrin alpha2; Mutation; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stents; Thrombectomy; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2021 |
Tirofiban 'bridging' therapy for patients with drug-eluting stents undergoing non-cardiac surgery.
Topics: Coronary Restenosis; Drug-Eluting Stents; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2010 |
Double interruption of antiplatelet therapy and tirofiban "bridging" for lung cancer resection.
Topics: Acute Coronary Syndrome; Aged; Biopsy, Needle; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Substitution; Drug-Eluting Stents; Humans; Lung; Lung Neoplasms; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Tirofiban; Tyrosine | 2012 |
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Restenosis; Enoxaparin; Eptifibatide; Flow Cytometry; Hemostatics; Heparin; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Thrombin; Tirofiban; Tyrosine | 2004 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Inflammation; Male; Middle Aged; Postoperative Period; Premedication; Stents; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.
Topics: Coronary Restenosis; Diabetic Angiopathies; Disease-Free Survival; Drug Combinations; Drug Implants; Eptifibatide; Follow-Up Studies; Humans; Immunosuppressive Agents; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Tirofiban; Tyrosine | 2006 |